ENDRA Life Sciences Inc.

NDRA Nasdaq SEC CIK 1681682
Follow ENDRA Life Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.5M +4.2% vs same quarter last year
EPS, diluted −$1.02 +51.4% vs same quarter last year
Operating cash flow −$1.8M −50.6% vs same quarter last year
Operating income −$1.7M −25.1% vs same quarter last year
Net income by quarter
−$4.1M
−$1M
−$1.2M
−$1.6M
−$3.2M
−$1.3M
$159.9K
−$1.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$15M−$10M−$5M$0$5MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$7M
FY24-−$11.5M
FY23-−$10.1M
FY22-−$13.2M
FY21-−$11.2M
FY20$0−$11.7M
FY19$0−$13.3M
FY18$6.2K−$9.8M
FY17$351.6K−$5.4M
FY16$515.6K−$2.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200000%−150000%−100000%−50000%0%50000%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22---
FY21---
FY20---
FY19---
FY18100%−146080.5%−158669.6%
FY1750.9%−1315.6%−1529.2%
FY1654.3%−347.5%−538.3%
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$5.2M
FY24−$7.4M
FY23−$9.6M
FY22−$13M
FY21−$11.2M
FY20−$10.8M
FY19−$8.6M
FY18−$7.8M
FY17−$3.3M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • ENDRA Life Sciences
  • Healthcare median
−200000%−150000%−100000%−50000%0%FY17FY19FY21FY23FY25
Show the numbers
YearENDRA Life SciencesHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18−158669.6%−49.6%
FY17−1529.2%−45.9%
FY16−538.3%−36%